chufangao/CTO huggingface dataset:
Clinical trial NCT02531724: Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery
Official title: Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery
Acronym: LEVOAKI
Sponsor: Sahlgrenska University Hospital, Sweden (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT02797977: A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Official title: A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Sponsor: Sierra Oncology LLC - a GSK company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 153.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-31
Primary completion date: 2020-04-08
Completion date: 2020-04-08
Plan to share individual participant data: NO
Clinical trial NCT04345289: Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
Official title: Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial
Acronym: CCAP
Sponsor: Hvidovre University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: DSMB advise due to high probability of futility
Enrollment: 147.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2021-03-16
Completion date: 2021-03-16
Plan to share individual participant data: NO
Clinical trial NCT03451123: FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors
Official title: FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Insufficient recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-23
Primary completion date: 2023-08-29
Completion date: 2023-08-29
Plan to share individual participant data: NO
Clinical trial NCT05355077: Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets
Official title: An Open-label, Dose-Escalation, Multiple-Dose Phase 1 Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets in Caucasian Healthy Subjects After Oral Administrations
Sponsor: Shanghai Vinnerna Biosciences Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Development strategy adjustment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-05-02
Primary completion date: 2022-08-01
Completion date: 2022-10-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04249336: Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH
Official title: Immediate And Sustained Treatment Response Of Commercially Available BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In Dentin Hypersensitivity - A Randomized Clinical Trial
Sponsor: Dow University of Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 140.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-27
Primary completion date: 2021-01-16
Completion date: 2021-01-16
Baseline population: 35 individuals per treatment group were recruited and enrolled in the study after clinical diagnosis of dentin hypersensitivity using air blast stimulus and SCHIFF cold air sensitivity scale. These participants were tested again for dentin hypersensitivity using mechanical stimulus and Visual Analogue Scale. After lost to follow up, statistical analysis was performed for 32 participants per group with baseline SCHIFF scale score of ≥2 and visual Analogue Scale score of ≥4.
Clinical trial NCT00585559: Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm
Official title: Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Enrollment: 120.0 (ESTIMATED)
Number of arms: 5.0
Start date: 2007-04-30
Primary completion date: 2023-10-26
Completion date: 2023-10-26
Plan to share individual participant data: NO
Clinical trial NCT03911076: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
Official title: A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)
Acronym: PVX2
Sponsor: PapiVax Biotech, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment/funding
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-22
Primary completion date: 2022-06-08
Completion date: 2022-06-08
Plan to share individual participant data: NO
Clinical trial NCT02065570: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
Official title: A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 514.0 (ACTUAL)
Number of arms: 4.0
Start date: 2014-05-01
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04831502: Bioavailability and Food Effect Study of Two Formulations of TAK-906
Official title: A Phase 1, Open Label, Randomized, Single-Dose, Replicate Crossover Study to Determine the Bioavailability of the Tablet Formulation Relative to the Capsule Formulation of TAK-906 and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Subjects
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-02
Primary completion date: 2022-02-02
Completion date: 2022-02-02
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04399889: hCT-MSCs for COVID19 ARDS
Official title: Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-18
Primary completion date: 2022-02-16
Completion date: 2022-02-16
Plan to share individual participant data: NO
Clinical trial NCT04770389: Randomized Study of Obicetrapib in Combination With Ezetimibe
Official title: A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia
Acronym: OCEAN
Sponsor: NewAmsterdam Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-02-23
Primary completion date: 2021-05-07
Completion date: 2021-06-30
Baseline population: The study was revised from a 12-week treatment period to an 8-week treatment period in response to the global COVID-19 pandemic. Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.
Plan to share individual participant data: NO
Clinical trial NCT03677830: Postoperative Pain Control & Relief in Neonates
Official title: Postoperative Pain Control & Relief in Neonates
Acronym: POPCORN
Sponsor: St. Louis University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Involved investigators no longer at the investigating center
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-19
Primary completion date: 2024-03-07
Completion date: 2024-03-07
Plan to share individual participant data: NO
Clinical trial NCT04058028: Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
Official title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 244.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-02-19
Primary completion date: 2023-07-25
Completion date: 2023-07-25
Baseline population: The Full Analysis Set (FAS) included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT06003075: Induction Chemo-Nivo in Unresectable Stage III NSCLC
Official title: Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-12-13
Primary completion date: 2024-07-05
Completion date: 2024-07-05
Plan to share individual participant data: NO
Clinical trial NCT03318016: Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Official title: Phase I Trial of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low enrollment, University Scientific Review Committee required study closure.
Enrollment: 5.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-12-15
Primary completion date: 2020-01-15
Completion date: 2021-01-20
Baseline population: Relapsed/Refractory Acute Myeloid Leukemia
Plan to share individual participant data: NO
Clinical trial NCT04230980: Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery
Official title: The Use of Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 74.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-28
Primary completion date: 2022-11-28
Completion date: 2022-12-16
Baseline population: 1 subject on the gabapentin arm and 3 subjects on the placebo arm were excluded as data collected from these participants was insufficient for analysis.
Plan to share individual participant data: NO
Clinical trial NCT01748825: AZD1775 for Advanced Solid Tumors
Official title: A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 10.0
Start date: 2012-12-19
Primary completion date: 2020-05-19
Completion date: 2020-05-19
Plan to share individual participant data: NO
Clinical trial NCT05753735: eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
Official title: eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF)
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Principal investigator left the institution.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-18
Primary completion date: 2024-03-14
Completion date: 2024-06-02
Baseline population: The number of participants analyzed in the standard perioperative antibiotic group is zero because no patients were randomized to this arm.
Limitations and caveats: The Principal Investigator left University Hospitals Cleveland Medical Center. Therefore, this clinical trial was terminated prematurely.
Plan to share individual participant data: YES
Clinical trial NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Official title: A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Sponsor: Impact Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-03
Primary completion date: 2020-09-24
Completion date: 2021-03-17
Plan to share individual participant data: NO
Clinical trial NCT03989635: Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
Official title: Randomized, Subject and Investigator Blinded, Placebo-controlled Study to Demonstrate the Anti-inflammatory Effect of Fevipiprant (QAW039) in Moderate to Severe Asthma Patients With High Sputum and Blood Eosinophils.
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Company Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-15
Primary completion date: 2021-06-14
Completion date: 2021-06-14
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Official title: A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Sponsor: Aravive, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to business reasons
Enrollment: 34.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-28
Primary completion date: 2023-08-14
Completion date: 2023-08-14
Plan to share individual participant data: NO
Clinical trial NCT03677115: Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine
Official title: Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine
Sponsor: China Medical University, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: no participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-01
Primary completion date: 2023-03-30
Completion date: 2023-03-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02898259: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Official title: A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funding was eliminated.
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-20
Primary completion date: 2018-10-23
Completion date: 2022-06-06
Baseline population: Participants enrolled in study
Clinical trial NCT03221751: Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)
Official title: Prazosin and CSF Biomarkers in mTBI
Acronym: PoND
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: staffing issues and COVID
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-01
Primary completion date: 2023-01-03
Completion date: 2023-12-05
Limitations and caveats: These results are not generalizable due to the small sample size.
Plan to share individual participant data: NO
Clinical trial NCT04362137: Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Official title: Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Acronym: RUXCOVID
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 432.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-02
Primary completion date: 2020-10-17
Completion date: 2020-10-17
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05051150: Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Caesarean Section
Official title: The Use of Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Cesarean Delivery: a Randomized Controlled Dose-finding Trial
Sponsor: Kasr El Aini Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: tachycardia and arrhythmia in the high doses groups 0.05 and 0.07 necessitate stopping the infusion
Enrollment: 18.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-15
Primary completion date: 2021-11-01
Completion date: 2021-11-01
Clinical trial NCT04452474: Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
Official title: A Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Sponsor: R-Pharm (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor's decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2020-11-16
Completion date: 2021-01-29
Clinical trial NCT03680911: NAC for Head Trauma-induced Anosmia
Official title: Early N-Acetyl Cysteine Treatment for Head Trauma-induced Anosmia
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Poor participant compliance
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-12
Primary completion date: 2020-01-07
Completion date: 2020-01-07
Plan to share individual participant data: NO
Clinical trial NCT03781089: Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Official title: Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Treated With Hemodialysis (PEARL-HD)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-20
Primary completion date: 2023-03-15
Completion date: 2023-03-15
Plan to share individual participant data: NO
IPD sharing description: Participant level data will not be shared.